The diabetes drug metformin can help stall progression
of calcium buildup in the coronary arteries of HIV-positive people with
metabolic abnormalities, potentially reducing their risk of cardiovascular
events,
- Published
- 14 March 2012
- By
- Liz Highleyman
Drug-drug interactions between direct-acting antiviral
agents for hepatitis C and some antiretroviral medications used to treat HIV
are common, but are often modest and can be managed
- Published
- 14 March 2012
- By
- Liz Highleyman
Current early infant diagnosis (EID)
protocols may need to be revised in the light of current WHO guidelines on the
prevention and treatment of HIV-infection in low-resourced
- Published
- 13 March 2012
- By
- Theo Smart
The Quad single-tablet regimen, an all-in-one pill
containing the experimental integrase inhibitor elvitegravir plus two other
antiretroviral drugs and a novel boosting agent, was as effective as
- Published
- 13 March 2012
- By
- Liz Highleyman
The
incidence of Kaposi’s Sarcoma (KS) among HIV-infected adults on ART in Uganda
and Kenya remains high (346 per 100,000 person-years) until the CD4 cell count
rises above
- Published
- 13 March 2012
- By
- Carole Leach-Lemens
Protease inhibitor-based treatment did not result in superior rates of viorologic suppression after two years when compared to NNRTI-based treatment when tested in a randomised
- Published
- 13 March 2012
- By
- Carole Leach-Lemens
Individuals still saw TB incidence reduction of two-thirds, but effect was not durable
Preliminary results from the Thibela Project – which looked at whether community-wide provision of isoniazid preventive therapy (IPT) in South African gold mines would improve TB control in these high-incidence sites.
- Published
- 12 March 2012
- From
-
Science Speaks
A number of papers at the 19th
Conference on Retroviruses and Opportunistic Infections presented advances in research on HIV-related brain impairment
and neurocognitive problems.
A couple of problems
- Published
- 12 March 2012
- By
- Gus Cairns
Two doses of Zostavax, a vaccine against shingles (herpes zoster), administered six weeks apart is “generally safe” for people living with HIV with CD4 counts of 200 or higher and undetectable viral loads, according to study results shared Wednesday, March 7, at the 19th Conference on Retroviruses and Opportunistic Infections (CROI).
- Published
- 12 March 2012
- From
-
AIDSMeds
A very low CD4 count in the past, and a history of smoking,
are the most consistent risk factors to emerge from large studies of risks
- Published
- 12 March 2012
- By
- Keith Alcorn
In an observational study, people with uncontrolled HIV experienced a loss in lung function at a higher rate than HIV-negative people and those with good viral control.
- Published
- 11 March 2012
- From
-
MedPage Today HIV/AIDS
Scientists, stymied for decades by the complexity of the human immunodeficiency virus, are making progress on several fronts in the search for a cure for HIV infections, a leading medical research conference was told this week.
- Published
- 11 March 2012
- From
-
Reuters
Scientists have discovered that blocking PD-1, an immune molecule that inhibits the immune response to viral infections, can have a significant effect on HIV-like illness in non-human primates.
- Published
- 11 March 2012
- From
-
Science Daily
The 19th
Conference on Retroviruses and Opportunistic Infections (CROI) heard this week that
a tenfold increase in medical male circumcision (MMC) in non-Muslim men in the
Rakai district
- Published
- 10 March 2012
- By
- Gus Cairns
Two studies of people with HIV
in Rakai, Uganda and Mombasa, Kenya presented at the 19th Conference on
Retroviruses and Opportunistic Infections show that the rate at
- Published
- 10 March 2012
- By
- Gus Cairns
Results from a recent small study indicate that Zolinza, a drug currently approved to treat a certain type of lymphoma, may successfully reduce the size of the latent HIV reservoir in HIV-positive adults taking antiretrovirals.
- Published
- 10 March 2012
- From
-
The AIDS Beacon
For treating children infected with HIV, the protease inhibitor combination of lopinavir/ritonavir (Kaletra) outperforms the non-nucleoside reverse transcriptase inhibitor nevirapine (Viramune), researchers suggested here.
- Published
- 09 March 2012
- From
- MedPage Today HIV/AIDS
Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV.
- Published
- 09 March 2012
- From
-
HIV / AIDS News From Medical News Today
Researchers from the Africa Centre for Health and Population Studies
have presented results which show that in areas where antiretroviral
therapy uptake is high (greater than 30%) people who do not have HIV are
38% less likely to acquire the virus than in areas of low uptake (less
than 10%).
- Published
- 09 March 2012
- From
-
UNAIDS
After seven years of research, the world's largest study of preventative tuberculosis (TB) therapy has found that untargeted, community-wide distribution of TB prevention drugs did not improve TB control on South African gold mines.
- Published
- 09 March 2012
- From
-
IRIN Plus News
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
New resources to support shared decision making in HIV care 21 May 2013There’s been lots of interest
recently in the concept of shared...
Pre-exposure prophylaxis (PrEP) – free webinar 18 April 2013As part of its European HIV prevention work, NAM is
collaborating...
Learning the basics about hepatitis C 05 April 2013If you are familiar with NAM’s
patient information materials, hopefully you...